[Treating hypercholesterolemia - when and how].
Treating hypercholesterolemia reduces cardiovascular events in secondary and primary prevention. Familial hypercholesterolemia is a high risk constellation per se and LDL-cholesterol should be lowered early in life and significantly. Some novel agents will broaden our therapeutic options. The MTP-inhibitor Lomitapide, that reduces LDL-cholesterol independently of the LDL-receptor, and PCSK9-inhibitors, that reduce LDL-cholesterol by blocking the degradation of the LDL-receptor, were approved recently. Both novel therapeutic principles are promising. Further trials have to address long term safety and - as first data suggest in case of PCSK9-inhibitors - the reduction of cardiovascular events. One can expect that these novel agents will improve the risk adapted therapy - in combination with well-established therapies or in case of intolerances as mono-therapy.